Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence companion study 60104 for CALGB 49907)

Annals of Oncology

Volumn 23, Issue 12, 2012, Pages 3075-3081

  Ruddy, K J ^a   Pitcher, B N ^b   Archer, L E ^b   Cohen, H J ^b   Winer, E P ^a   Hudis, C A ^c   Muss, H B ^d   Partridge, A H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antineoplastic combined chemotherapy protocols; Breast neoplasms; Geriatrics; Medication adherence; Patient compliance; Toxicity

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

AGED; ANEMIA; ARTICLE; ATAXIA; BLOOD CLOTTING DISORDER; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; KIDNEY FAILURE; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPENIC INFECTION; NEUTROPHIL COUNT; PAIN; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SIDE EFFECT; SPEECH DISORDER; THERAPY EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MEDICATION ADHERENCE; METHOTREXATE; PATIENT COMPLIANCE;

EID: 84869821658     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds133     Document Type: Article

References (23)

1. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11(1): 44-47.
2. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009; 59(1): 56-66.
3. Zedler P, Kakad P, Colilla S et al. Does packaging with a calendar feature improve adherence to self-administered medication for long-term use? A systematic review. Clin Ther 2011; 33(1): 62-73.
4. Partridge AH, Wang PS, Winer EP et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 21(4): 602-606.
5. Hershman DL, Kushi LH, Shao T et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010; 28(27): 4120-4128.
6. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001; 19(2): 322-328.
7. Muss HB, Berry DA, Cirrincione CT et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360(20): 2055-2065.
8. Partridge AH, Archer L, Kornblith AB et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010; 28(14): 2418-2422; 7. CTCAE v.2, 1999.
9. Weingart SN, Toro J, Spencer J et al. Medication errors involving oral chemotherapy. Cancer 2010; 116(10): 2455-2464.
10. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 2006; 71(1-2): 1-9.
11. Partridge AH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol 2006; 17(2): 183-184.
12. Owusu C, Buist DS, Field TS et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008; 26(4): 549-555.
13. Thompson AM, Johnson A, Quinlan P et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 2011; 125(1): 279-287.
14. McCowan C, Shearer J, Donnan PT et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008; 99(11): 1763-1768.
15. Dezentje VO, van Blijderveen NJ, Gelderblom H et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 2010; 28(14): 2423-2429.
16. Mayer EL, Partridge AH, Harris LN et al. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat 2009; 117(3): 615-623.
17. Bonadonna MD, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Eng J Med 1981; 304: 10-14.
18. Waterhouse DM, Calzone KA, Mele C et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993; 11(6): 1189-1197.
19. Choo PW, Rand CS, Inui TS et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37: 846-857.
20. Fink AK, Gurwitz J, Rakowski W et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 2004; 22(16): 3309-3315.
21. Haynes RB. A critical review of the 'determinants' of patient compliance with therapeutic regimens. In Sackett DL, Haynes RB (eds), Compliance with Therapeutic Regimens. Baltimore, MD: The Johns Hopkins University Press 1976; 26-39.
22. Leventhal H, Nerenz D, Leventhal E et al. The behavioral dynamics of clinical trials. Prev Med 1991; 20: 132-146.
23. Goldhirsch A, Colleoni A, Castiglione-Gertsch M et al. Adding adjuvant CMF chemotherapy to either sradiotherapy or tamoxifen: are all CMFs alike? Ann Oncol 1998; 9: 489-493.